Literature DB >> 19882659

Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease.

Petra Steinacker1, Wolfgang Rist, Magdalena Swiatek-de-Lange, Stefan Lehnert, Sarah Jesse, Alice Pabst, Hayrettin Tumani, Christine A F von Arnim, Eva Mitrova, Hans A Kretzschmar, Martin Lenter, Jens Wiltfang, Markus Otto.   

Abstract

Until today, a definite diagnosis of Creutzfeldt-Jakob disease (CJD) can only be made neuropathologically. At lifetime the early and differential diagnosis is often a problem. With SELDI we analyzed cerebrospinal fluid (CSF) from 32 CJD patients, 32 patients having other dementive diseases and 31 non-demented control subjects for diagnosis-dependent protein pattern differences. In a screening set of patients, peaks that discriminate best between groups were identified. These peaks were subsequently analyzed using an independent validation set of patients. Diagnostic accuracies were compared with established markers like tau protein and 14-3-3-protein. Potential marker proteins were purified and identified by LC-MS/MS. In the validation set only one peak of 8.6 kDa out of ten in the screening set could be confirmed. This protein was identified to be ubiquitin and increased levels in CSF (but not in serum) of CJD patients were confirmed by Western blot. Ubiquitin allows the correct diagnoses of that CJD cases missed by tau protein or 14-3-3-protein. We conclude that ubiquitin is a promising additional CSF biomarker for diagnosis of CJD, especially in differential diagnostically difficult cases. The selective increase of ubiquitin in CSF of CJD patients might point to an involvement of ubiquitin in pathophysiological process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19882659     DOI: 10.1002/pmic.200900246

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  11 in total

Review 1.  Recent advances in quantitative neuroproteomics.

Authors:  George E Craft; Anshu Chen; Angus C Nairn
Journal:  Methods       Date:  2013-04-25       Impact factor: 3.608

Review 2.  Application of "Omics" Technologies for Diagnosis and Pathogenesis of Neurological Infections.

Authors:  Farshid Noorbakhsh; Atefeh Aminian; Christopher Power
Journal:  Curr Neurol Neurosci Rep       Date:  2015-09       Impact factor: 5.081

Review 3.  Improper Proteostasis: Can It Serve as Biomarkers for Neurodegenerative Diseases?

Authors:  Ankur Rakesh Dubey; Som Mohanlal Patwa; Sumit Kinger; Yuvraj Anandrao Jagtap; Prashant Kumar; Sarika Singh; Rohan Dhiman; Hem Chandra Jha; Amit Mishra
Journal:  Mol Neurobiol       Date:  2022-03-19       Impact factor: 5.682

4.  Proteome Analysis of Potential Synaptic Vesicle Cycle Biomarkers in the Cerebrospinal Fluid of Patients with Sporadic Creutzfeldt-Jakob Disease.

Authors:  Chunyu Wang; Deming Zhao; Syed Zahid Ali Shah; Wei Yang; Chaosi Li; Lifeng Yang
Journal:  Mol Neurobiol       Date:  2016-08-25       Impact factor: 5.590

5.  cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.

Authors:  Philipp Spitzer; Hans Wolfgang Klafki; Kaj Blennow; Luc Buée; Hermann Esselmann; Sanna-Kaisa Herruka; Connie Jimenez; Peter Klivenyi; Piotr Lewczuk; Juan Manuel Maler; Katrin Markus; Helmut E Meyer; Chris Morris; Thorsten Müller; Markus Otto; Lucilla Parnetti; Hilkka Soininen; Susanna Schraen; Charlotte Teunissen; Laszlo Vecsei; Henrik Zetterberg; Jens Wiltfang
Journal:  Int J Alzheimers Dis       Date:  2010-09-19

6.  CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Patrick Oeckl; Petra Steinacker; Stefan Lehnert; Sarah Jesse; Hans A Kretzschmar; Albert C Ludolph; Markus Otto; Boris Ferger
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

Review 7.  Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic review.

Authors:  Orthodoxia Nicolaou; Andreas Kousios; Andreas Hadjisavvas; Bernard Lauwerys; Kleitos Sokratous; Kyriacos Kyriacou
Journal:  J Cell Mol Med       Date:  2016-11-23       Impact factor: 5.310

8.  Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders.

Authors:  Simon Sjödin; Oskar Hansson; Annika Öhrfelt; Gunnar Brinkmalm; Henrik Zetterberg; Ann Brinkmalm; Kaj Blennow
Journal:  Proteomics Clin Appl       Date:  2017-11-02       Impact factor: 3.494

9.  CSF Ubiquitin Levels Are Higher in Alzheimer's Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease.

Authors:  Samir Abu-Rumeileh; Patrick Oeckl; Simone Baiardi; Steffen Halbgebauer; Petra Steinacker; Sabina Capellari; Markus Otto; Piero Parchi
Journal:  Biomolecules       Date:  2020-03-25

10.  Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease.

Authors:  Simon Sjödin; Gunnar Brinkmalm; Annika Öhrfelt; Lucilla Parnetti; Silvia Paciotti; Oskar Hansson; John Hardy; Kaj Blennow; Henrik Zetterberg; Ann Brinkmalm
Journal:  Alzheimers Res Ther       Date:  2019-09-14       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.